The Therapeutic Potential of EGCG and Pro-EGCG in Mitigating Ovarian Hyperstimulation Syndrome: Unraveling the Modulatory Mechanism through the VEGF Pathway
International Journal of Biological Sciences · 2025-04-22 · 21 (7) · 3045-3060
DOI: 10.7150/ijbs.98653 ↗At a glance
Journal article in International Journal of Biological Sciences, published on 2025-04-22. Written by Sijia Wang and 12 co-authors. Institution: Assisted Reproductive Technology Unit, Department of Obstetrics and Gynecology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong S…. Major MEDLINE topics: Protease Inhibitors, Radiation-Protective Agents, Urokinase-Type Plasminogen Activator, Ovarian Hyperstimulation Syndrome. Cited 5 times so far (Crossref). The full text is freely available in PubMed Central.
Abstract (original language)
Ovarian hyperstimulation syndrome (OHSS) is a severe complication of controlled ovarian hyperstimulation (COH) during in vitro fertilization (IVF) treatment, characterized by increased capillary permeability. Vascular endothelial growth factor (VEGF) is a key mediator in OHSS, with serum VEGF levels correlating with its severity. In this study, we investigated the therapeutic potential of (-)-epigallocatechin-3-gallate (EGCG) and its derivative, Pro-EGCG, in mitigating OHSS. Using both in vitro and in vivo models, including primary human granulosa-lutein cells, the human granulosa-like tumor KGN cell line, and a rat OHSS model induced with pregnant mare serum gonadotropin, we found that EGCG and Pro-EGCG significantly reduced OHSS progression. This was supported by histological analyses, reductions in ovarian weight, and decreased VEGF expression at both transcriptomic and proteomic levels. Mechanistic studies revealed that EGCG and Pro-EGCG inhibit TGF-β-induced VEGF production through suppression of the TGF-β/Smad and PKA-CREB signaling pathways. RNA sequencing further validated the downregulation of VEGF expression following treatment. These findings highlight the potential of EGCG as a novel adjuvant therapy for managing OHSS, providing a mechanistic basis for its clinical application.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Assisted Reproductive Technology Unit, Department of Obstetrics and Gynecology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, 999077, China.
- Center for Reproductive Medicine, Henan Key Laboratory of Reproduction and Genetics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450003, China.
- The Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
Cite
APA
Wang, S., Fang, L., Cong, L., Jia, Q., Wu, W., Zhao, M., Li, T., Chung, J. P. W., Fung, K. K., Lam, V. C. M., Sun, Y., Cheng, J. C., & Chan, D. Y. L. (2025). The Therapeutic Potential of EGCG and Pro-EGCG in Mitigating Ovarian Hyperstimulation Syndrome: Unraveling the Modulatory Mechanism through the VEGF Pathway. International Journal of Biological Sciences, 21(7), 3045-3060. https://doi.org/10.7150/ijbs.98653
Vancouver
Wang S, Fang L, Cong L, Jia Q, Wu W, Zhao M, et al. The Therapeutic Potential of EGCG and Pro-EGCG in Mitigating Ovarian Hyperstimulation Syndrome: Unraveling the Modulatory Mechanism through the VEGF Pathway. International Journal of Biological Sciences. 2025;21(7):3045-3060. doi:10.7150/ijbs.98653
BibTeX
@article{Wang2025,
author = {Wang, Sijia and Fang, Lanlan and Cong, Luping and Jia, Qiongqiong and Wu, Waner and Zhao, Mingpeng and Li, Tinchiu and Chung, Jacqueline Pui Wah and Fung, Ka Kei and Lam, Vivian Ching Man and Sun, Yingpu and Cheng, Jung-Chien and Chan, David Yiu Leung},
title = {The Therapeutic Potential of EGCG and Pro-EGCG in Mitigating Ovarian Hyperstimulation Syndrome: Unraveling the Modulatory Mechanism through the VEGF Pathway},
journal = {International Journal of Biological Sciences},
year = {2025},
volume = {21},
number = {7},
pages = {3045--3060},
doi = {10.7150/ijbs.98653}
}
EUVIMED